IMM2510

DRUG4 trials

Sponsors

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Conditions

Advanced Solid TumorsHCCNSCLCTNBC

Phase 1

IMM2510, a PD-L1 and VEGF Bispecific Fusion Protein, in Patients With Advanced Solid Tumors

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.Advanced Solid Tumors

Start: 2021-08-18End: 2024-10-31Target: 108Updated: 2023-08-02

A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Solid Tumors

RecruitingNCT06764836

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.Advanced Solid Tumors, HCC

Start: 2024-07-23End: 2026-01-27Target: 108Updated: 2025-01-08

A Study of IMM2510 + IMM01 Combination Therapy in Patients With Advanced Solid Tumors

Not yet recruitingNCT07170787

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.Advanced Solid Tumors

Start: 2025-10-15End: 2029-07-31Target: 104Updated: 2025-09-12

Phase 2

A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer

Not yet recruitingNCT06746870

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.NSCLC, TNBC

Start: 2024-12-31End: 2026-12-31Target: 148Updated: 2024-12-24

Related Papers

Phase I study of IMM2510, a PD-L1/ VEGF bispecific antibody, in participants with advanced IO-treated SQ-NSCLC.

Journal of Clinical Oncology2026-05-28

IMM2510, an anti-PD-L1/VEGF bispecific antibody fusion protein, in patients with R/R STS: A phase Ib expansion study.

Journal of Clinical Oncology2025-05-28

IMM2510, an anti-PD-L1/VEGF bispecific antibody fusion protein, in patients with advanced solid tumors: A phase I dose-escalation study.

Journal of Clinical Oncology2024-06-015 citations